Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left"> Event</td><td align="center">Docetaxel alone (<svg height="10.9125" id="M5" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 35.099998 10.9125" width="35.099998" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.9125)">
<g transform="translate(72,-63.27)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
<tspan style="font-size: 12.50px; " x="9.6773224" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="21.71771" y="0">3</tspan>
</text>
</g>
</g>
</svg>)</td><td align="center">Gefitinib + docetaxel (<svg height="11.1" id="M6" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 35.099998 11.1" width="35.099998" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.1)">
<g transform="translate(72,-63.12)">
<text transform="matrix(1,0,0,-1,-71.95,63.35)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
<tspan style="font-size: 12.50px; " x="9.6773224" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="21.71771" y="0">5</tspan>
</text>
</g>
</g>
</svg>)</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Dehydration</td><td align="center">0</td><td align="center">3</td></tr><tr><td align="left">Fatigue</td><td align="center">0</td><td align="center">1</td></tr><tr><td align="left">Stomatitis</td><td align="center">0</td><td align="center">1</td></tr><tr><td align="left">Diarrhoea</td><td align="center">3</td><td align="center">2</td></tr><tr><td align="left">Hypokalemia</td><td align="center">0</td><td align="center">1</td></tr><tr><td align="left">Anorexia</td><td align="center">1</td><td align="center">0</td></tr><tr><td align="left">Vomiting</td><td align="center">1</td><td align="center">0</td></tr><tr><td align="left">Neutropenia</td><td align="center">0</td><td align="center">1</td></tr><tr><td align="left">Pneumonia</td><td align="center">0</td><td align="center">1</td></tr><tr><td align="left">Infection</td><td align="center">0</td><td align="center">1</td></tr><tr><td align="left">Catheter sepsis</td><td align="center">0</td><td align="center">1</td></tr><tr><td align="left">Chest pain</td><td align="center">0</td><td align="center">1</td></tr><tr><td align="left">Subclavian vein thrombosis</td><td align="center">1</td><td align="center">0</td></tr><tr><td align="left">Vertigo</td><td align="center">1</td><td align="center">0</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><svg height="7.1374998" id="M7" style="vertical-align:-0.10033pt" version="1.1" viewbox="0 0 7.8874998 7.1374998" width="7.8874998" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,7.1375)">
<g transform="translate(72,-66.29)">
<text transform="matrix(1,0,0,-1,-71.95,66.44)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
</text>
</g>
</g>
</svg>: number of patients.<br/></td></tr></table>

International Scholarly Research Notices

tab3

Table 3

Table 3: Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial 

Table 3 | Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial 